Susan G. Gray

Susan G. Gray

Auto-generated profile, based on publicly available information

Susan G. Gray

School of Pharmacy The University of Queensland Brisbane Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ANAsma Nafisa
Asma Nafisa
SGSusan G. Gray
Susan G. Gray
YCYingnan Cao
Yingnan Cao
TWTinghuai Wang
Tinghuai Wang
Suowen XuSuowen Xu
Suowen Xu
Peter James LittlePeter James Little
Peter James Little

24 March 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
SGSusan G. Gray
Susan G. Gray
TMTreasure M. McGuire
Treasure M. McGuire
NCNeale Cohen
Neale Cohen
Peter James LittlePeter James Little
Peter James Little

23 March 2018 in Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
SGSusan G. Gray
Susan G. Gray
ASArianne N. Sweeting
Arianne N. Sweeting
TMTreasure M. Mcguire
Treasure M. Mcguire
NCNeale Cohen
Neale Cohen
GRGlynis Ross
Glynis Ross
Peter James LittlePeter James Little
Peter James Little

11 August 2019 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Open access
PDF file
SGSusan G. Gray
Susan G. Gray
TMTreasure M. McGuire
Treasure M. McGuire
Off‐label or unlicensed medicines use is extremely common in obstetric and paediatric clinical practice and necessitates greater emphasis on the underlying evidence of a medicines safety or efficacy. This creates significant challenges for pharmacists relating to the supply and use of medicines in this setting. Understanding how and why unlicensed or off‐label medicine use occurs, together with the underlying evidence base, is critical for supporting the quality use of medicines. Addressing issues surrounding unlicensed or off‐label medicine use in a collaborative manner with prescribers and patients can help reduce unnecessary patient concern, possible non‐adherence and risk of suboptimal treatment outcomes. This review summarises current evidence and challenges surrounding off‐label and unlicensed medicine use in the obstetric and paediatric clinical setting from the perspective of key stakeholders. It aims to support pharmacists in their evaluation of the appropriateness of off‐label and unlicensed medicine use, and provide strategies to help manage these challenging medicines management decisions.